One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1182/blood-2019-128275
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 13, 2019 |
Affiliation: The University of Texas MD Anderson Cancer Center, Duke University, European Institute of Oncology, ImmunoGen (United States), Istituto Oncologico Romagnolo, Roswell Park Cancer Institute, University of Alabama at Birmingham, Centro de Investigación Biomédica en Red de Cáncer, Hospital Universitari i Politècnic La Fe, Dana-Farber Cancer Institute, Moffitt Cancer Center, Centre Hospitalier Universitaire de Besançon
A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, and Other CD123-Positive Hematologic Malignancies
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
